Fibromyalgia is not a psychiatric disorder, a connective tissue disease, or a "central sensitization syndrome" in the sense the current literature most often uses that phrase. It is a clinical phenotype produced by at least four mechanistically distinct upstream lesions: mitochondrial dysfunction that compromises ATP production in muscle and nerve tissue, mast cell activation that sensitizes peripheral and central pain pathways, small fiber neuropathy that is now documented in approximately half of all fibromyalgia patients, and gut-brain axis dysfunction that drives the sustained neuroinflammation underlying the central sensitization. Most patients have features of all four lesions. Lyrica, Cymbalta, and gabapentin act on downstream pain processing. They do not address the upstream lesions. This is why response is so often partial, why side effects so often outweigh benefits over time, and why fibromyalgia patients commonly describe their experience as "getting worse on the medications that are supposed to be helping." The standard model treats the central sensitization as the disease. The Host Capacity Model treats the central sensitization as the readout of upstream lesions that are continuously generating the pain signal.

The clinical pattern that defines treatment-resistant fibromyalgia

A patient presents with widespread musculoskeletal pain that has progressed over years, fatigue that is profound and unrefreshing despite sleep, cognitive dysfunction that the patient calls "fibro fog," sleep that feels disrupted even when duration is adequate, sensitivities to light, sound, temperature, and chemical exposure, and a constellation of overlapping conditions that include irritable bowel syndrome, migraine, restless legs, anxiety, and depression. The diagnostic journey has typically taken 5 to 10 years and involved multiple specialists. Rheumatology workup has ruled out connective tissue disease. Neurological workup has ruled out demyelinating disease. The fibromyalgia diagnosis arrives by exclusion, often with the implicit message that the workup has not found anything organic and the symptoms are largely psychological.

The treatment cascade follows the standard guidelines. Pregabalin (Lyrica). Duloxetine (Cymbalta) or milnacipran. Cyclobenzaprine for sleep. Tramadol for pain breakthroughs. Cognitive behavioral therapy. Graded exercise. Sleep hygiene education. Mindfulness-based stress reduction.

Some patients respond meaningfully to this combination. Many do not. The clinical trials of pregabalin and duloxetine in fibromyalgia show modest effect sizes; approximately 30 to 40 percent of patients achieve a 30 percent reduction in pain in randomized trials. That means 60 to 70 percent of patients do not achieve even modest response. For patients who do respond, side effects (weight gain, cognitive blunting, sexual dysfunction, fatigue, dizziness) often outweigh the pain reduction over time. The standard treatment paradigm leaves a large fraction of patients with inadequate relief, substantial medication burden, and a sense that medicine has nothing else to offer them.

This pattern is well-documented in the fibromyalgia literature, including in patient-reported outcome studies that show progressive disengagement from formal medical care over time. Patients turn to functional medicine, supplements, integrative approaches, and self-experimentation, often with mixed results because the field of alternatives is fragmented and many of the proposed mechanisms are speculative.

The Host Capacity Model approach to fibromyalgia consolidates the mechanistic literature into a four-driver framework that explains the variable response to existing treatments and points to upstream interventions that the current treatment paradigm does not address. The standard medications retain their place as containment. The upstream work addresses the lesions producing the input into the central sensitization circuit.

Why the current fibromyalgia model produces variable results

The dominant current model of fibromyalgia is the "central sensitization" model. Pain processing in the central nervous system is amplified. The amplification produces hypersensitivity to normal stimuli (allodynia) and exaggerated response to painful stimuli (hyperalgesia). Treatment targets the pain processing itself: pregabalin and gabapentin act on alpha-2-delta calcium channels reducing neurotransmitter release, duloxetine and milnacipran act on serotonin and norepinephrine reuptake increasing descending inhibition, cyclobenzaprine acts at the brainstem to reduce muscle tone and improve sleep architecture.

This model has produced effective acute treatments. It has not produced curative treatments. Long-term outcomes are modest. The model is correct in describing what is happening in central pain processing. It is incomplete in describing why the central sensitization developed in the first place and why it persists despite treatment.

The questions the current model does not adequately address: what triggers the central sensitization in a specific patient? Why do some patients develop central sensitization after a specific event (infection, trauma, surgery) while others develop it gradually without an identifiable trigger? What sustains the sensitization despite treatment that targets the relevant neurotransmitter systems? Why do specific subsets of fibromyalgia patients have additional findings (small fiber neuropathy, mast cell activation, mitochondrial markers, gut dysfunction) that the central sensitization model does not predict?

These questions are addressed by the research literature on the upstream mechanisms. The literature has expanded substantially over the past decade. It has not yet propagated into clinical practice in a coherent framework.

The Host Capacity Model framework consolidates this literature. The four-driver structure identifies the upstream lesions producing the input into the central sensitization circuit. Different patients have different dominant drivers. The framework points to different interventions for different cases. The conventional medications remain useful as containment while the upstream work proceeds.

The four mechanistic drivers of fibromyalgia

Driver 1: Mitochondrial dysfunction in muscle and nerve tissue

The fibromyalgia muscle is bioenergetically compromised. This is one of the most consistent findings in the research literature, supported by work from Cordero and colleagues, Sánchez-Domínguez and colleagues, and others. Patients with fibromyalgia have reduced coenzyme Q10 levels in mononuclear cells, increased oxidative stress markers, reduced ATP production capacity in muscle biopsies, and increased lactate-to-pyruvate ratios suggesting impaired mitochondrial function.

The mechanism connects to the broader Host Capacity Model framework. The CD38-NAD+-SIRT3 cascade described in the dedicated article operates in fibromyalgia as it does in other chronic inflammatory states. CD38 is induced by inflammation. NAD+ is depleted. SIRT3 activity falls. Mitochondrial proteome regulation fails. ATP output falls in cells throughout the body, but particularly in tissues with high bioenergetic demand: muscle, nerve, brain.

The clinical consequence in muscle is sustained low-grade compromise of contractile function and slowed recovery from exertion. This is the mechanism behind post-exertional malaise in fibromyalgia, where exercise that should be tolerated produces disproportionate worsening. The muscle has the structures, has the substrates, but cannot generate the ATP at the rate the work demands. The patient experiences this as pain, fatigue, and what often gets labeled "deconditioning" but is actually a primary bioenergetic compromise.

The clinical consequence in nerve tissue is sensitization of peripheral nociceptors. The bioenergetically compromised nerve has reduced membrane potential, lower threshold for activation, and impaired recovery between depolarizations. The same stimuli that would not produce pain in a healthy nerve produce pain signaling in the compromised one. The peripheral input into the central sensitization circuit is increased not because the nerves are more numerous but because each existing nerve is more easily triggered.

The clinical signature of Driver 1 includes profound post-exertional fatigue, sleep that does not restore energy, cognitive symptoms that worsen with mental exertion, and pain that is disproportionate to physical activity. Response to mitochondrial-targeted supplements (CoQ10 ubiquinol form, magnesium glycinate, riboflavin, ALA) often produces meaningful improvement when Driver 1 is dominant.

Driver 2: Mast cell activation and the pain-sensitization loop

Mast cells are mechanistically central to fibromyalgia in ways that the clinical literature is finally beginning to recognize. Skin biopsy studies in fibromyalgia patients have documented elevated mast cell density compared to controls. Multiple studies have shown elevated tryptase, histamine, and other mast cell mediators in fibromyalgia patients. The MCAS-fibromyalgia overlap is substantial, with approximately 50 to 80 percent of fibromyalgia patients meeting at least partial criteria for MCAS depending on the diagnostic threshold used.

The mechanism is direct. Mast cells release mediators (histamine, tryptase, prostaglandin D2, leukotrienes, nerve growth factor, tumor necrosis factor) that sensitize peripheral nociceptors. They also release mediators that affect the central nervous system through both vagal afferent signaling and through direct mast cell presence in the meninges and CNS. The mast cell activation contributes to the peripheral input into central sensitization AND to the central sensitization process itself.

The four-pattern MCAS framework described in the article on treatment-resistant MCAS applies. Fibromyalgia patients often have Pattern A barrier-driven MCAS, Pattern B neuroimmune/vagal MCAS, or some combination. Pattern A is more common when concurrent gut symptoms are prominent. Pattern B is more common when autonomic features are prominent (POTS-spectrum, dysautonomia, the constellation described in the POTS article).

The therapeutic implications are direct. Mast cell stabilization (cromolyn, ketotifen, quercetin) reduces fibromyalgia pain in patients with dominant Driver 2. H1 and H2 antihistamines provide partial relief. The natural mast cell stabilizers (quercetin, luteolin, vitamin C, vitamin D) operate through this mechanism. The recognition that fibromyalgia has a substantial mast cell component changes the treatment approach for the patients in whom this driver is dominant.

The clinical signature of Driver 2 includes triggers consistent with mast cell activation: temperature changes, alcohol, aged or fermented foods, weather sensitivity, perimenstrual flares, environmental sensitivities to perfumes and cleaning products, and concurrent skin findings (flushing, dermatographism, atypical reactions to mosquito bites or other minor exposures). Patients often respond well to a low-histamine dietary trial.

Driver 3: Small fiber neuropathy

This driver represents one of the most significant findings in fibromyalgia research in the past decade. Beginning with the work of Oaklander and colleagues in 2013, multiple research groups have documented small fiber neuropathy in approximately 30 to 50 percent of fibromyalgia patients on skin biopsy. The neuropathy is real, objectively measurable, and pathophysiologically distinct from the "central sensitization without peripheral pathology" framing that dominated the prior literature.

Small fiber neuropathy involves the unmyelinated and lightly myelinated C-fibers and A-delta fibers that mediate pain, temperature, and autonomic function. These fibers are bioenergetically expensive because they conduct without the saltatory conduction that myelinated fibers benefit from. When the bioenergetic state is compromised, these fibers are among the first to dysfunction. The dysfunction may include outright fiber loss (documented on skin biopsy) or functional compromise without obvious loss.

The mechanism of small fiber neuropathy in fibromyalgia is incompletely characterized. Likely contributors include: the mitochondrial dysfunction described in Driver 1 (because small fibers are bioenergetically expensive); mast cell activation that produces local inflammation around peripheral fibers; ion channel dysfunction (sodium channel variants have been documented in some fibromyalgia patients); autoimmune contributions (fibromyalgia patients have elevated rates of anti-neural antibodies); and metabolic factors including impaired glucose tolerance even at the prediabetic level.

The clinical implications of small fiber neuropathy in fibromyalgia are significant. The diagnosis can be objectively confirmed by skin biopsy with epidermal nerve fiber density assessment. Treatments approaches that address peripheral nerve health become relevant: alpha-lipoic acid (well-studied in diabetic small fiber neuropathy), the broader B-vitamin support (particularly B1 thiamine and B12 methylcobalamin), magnesium, and addressing any contributing metabolic factors. The recognition of small fiber neuropathy as a peripheral driver shifts the treatment approach away from purely central interventions.

The clinical signature of Driver 3 includes burning or shooting pain (not just dull aching), temperature sensitivity (particularly to cold), autonomic features (orthostatic symptoms, gastrointestinal motility changes), and patchy or asymmetric pain distribution. Skin biopsy is the definitive test but is performed in relatively few centers; the clinical pattern often suggests the diagnosis before biopsy confirmation.

Driver 4: Gut-brain axis dysfunction and sustained neuroinflammation

The gut-brain axis contributes to fibromyalgia through multiple mechanisms. Lipopolysaccharide (LPS) translocation across a compromised gut barrier produces sustained systemic inflammation that affects pain processing through TLR4 activation on microglia and other immune cells. The microbiome composition shifts in fibromyalgia patients toward a dysbiotic state characterized by reduced obligate anaerobic core taxa (Faecalibacterium prausnitzii, Akkermansia muciniphila) and expanded facultative anaerobes (Enterobacteriaceae). The dysbiosis is mechanistically similar to that seen in the conditions described in the recurrent SIBO article.

SIBO specifically has elevated prevalence in fibromyalgia. Studies have documented rates of 70 to 80 percent positive breath testing in fibromyalgia populations compared to baseline rates of 10 to 15 percent in healthy controls. The mechanism is bidirectional: the gut dysfunction produces systemic inflammation that drives the central sensitization, AND the sympathetic dominance and autonomic compromise that often accompanies fibromyalgia produces gut dysmotility that supports SIBO development.

The vagal contribution is significant. The cholinergic anti-inflammatory pathway, described in the POTS article, lowers the immune activation threshold throughout the body. When vagal tone is compromised (which is common in fibromyalgia patients, particularly those with concurrent POTS-spectrum symptoms), the systemic inflammatory tone rises and contributes to the pain amplification.

The clinical signature of Driver 4 includes concurrent gastrointestinal symptoms (bloating, food sensitivities, IBS-pattern bowel changes), post-meal worsening of fibromyalgia symptoms, sensitivity to specific food categories (FODMAPs, high-histamine foods), concurrent migraine or other gut-brain axis conditions, and onset or worsening following gastrointestinal events (infection, antibiotics, food poisoning).

When drivers combine

Most fibromyalgia cases have features of more than one driver. The most common combinations:

Driver 1 (mitochondrial) and Driver 2 (mast cell) frequently combine because the inflammation that activates mast cells also drives the CD38-NAD+ depletion that compromises mitochondrial function. Patients with this combination respond to both mitochondrial cofactor support and mast cell stabilization.

Driver 2 (mast cell) and Driver 4 (gut-brain) frequently combine because Pattern A barrier-driven MCAS is mechanistically related to the gut barrier failure that drives systemic inflammation. Treatment addresses both layers concurrently.

Driver 3 (small fiber neuropathy) often combines with Driver 1 (mitochondrial) because the small fibers are bioenergetically expensive and are among the first tissues to show functional compromise in mitochondrial states.

Driver 4 (gut-brain) often combines with all the others because the systemic inflammatory tone affects mast cells, mitochondria, and small fibers simultaneously.

The clinical task is to identify the dominant driver in the specific patient, name the contributing drivers, and sequence interventions accordingly.

Why Lyrica and Cymbalta produce variable response

The pharmacological mechanism of pregabalin (Lyrica) is binding to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, reducing release of glutamate, norepinephrine, and substance P. This reduces the central pain amplification. It does not address the peripheral input. For patients whose central sensitization is being driven by ongoing peripheral input from any of the four drivers above, pregabalin reduces the amplification while the input continues. Response is partial.

The pharmacological mechanism of duloxetine (Cymbalta) is serotonin and norepinephrine reuptake inhibition, increasing the activity of descending pain inhibition. This increases the brain's capacity to dampen incoming pain signals. It does not reduce the signal itself. Same outcome: partial response.

Tramadol acts as both a weak opioid agonist and a serotonin/norepinephrine reuptake inhibitor. It addresses central processing without addressing peripheral input. Same outcome.

Cyclobenzaprine, gabapentin, and other commonly prescribed medications operate similarly: downstream effects on pain processing without addressing the upstream lesions. Each is reasonable as containment. None addresses the lesion.

This explains the partial response, the variable response, the response that decays over time, and the substantial side effect burden. The medications are doing what they are designed to do. What they are designed to do is incomplete because the lesion is not where the medication is acting.

The framework predicts that patients with dominant Driver 1 will respond well to mitochondrial support added to standard treatment, patients with dominant Driver 2 will respond well to mast cell stabilization added to standard treatment, patients with dominant Driver 3 will respond well to peripheral nerve support added to standard treatment, and patients with dominant Driver 4 will respond well to gut work added to standard treatment. Each combination is more effective than standard treatment alone because each combination addresses the peripheral input alongside the central processing.

The patterns that suggest the framework applies

Fibromyalgia cases that benefit most from a Host Capacity Model approach share specific features: inadequate response to first-line treatments (pregabalin, duloxetine, gabapentin, milnacipran); side effects from standard treatments that outweigh benefits; profound post-exertional fatigue suggesting Driver 1; concurrent MCAS-spectrum symptoms suggesting Driver 2; burning or shooting pain quality (not just dull aching) suggesting Driver 3; concurrent gastrointestinal symptoms suggesting Driver 4; pattern of multiple overlapping syndromes (fibromyalgia + IBS + migraine + POTS + hEDS-spectrum hypermobility); onset or worsening following identifiable triggers (infection, surgery, severe stress, antibiotic course); family history of similar overlapping syndromes; and a sense from the patient that the standard medical model has not captured what is happening in their body.

What restoration looks like

A treatment approach anchored in the four-driver framework looks different from standard fibromyalgia care. The conventional medications continue where they are providing benefit and the side effect profile is acceptable. The upstream work proceeds in parallel.

For Driver 1 (mitochondrial) cases: CoQ10 in ubiquinol form (200-400 mg daily); magnesium glycinate (400-600 mg daily, divided); riboflavin (100-400 mg daily); alpha-lipoic acid (300-600 mg daily); NAD+ precursor supplementation (nicotinamide riboside or NMN); sleep optimization and consistent meal timing because the compromised mitochondrial state cannot buffer disruptions; address the upstream drivers of the bioenergetic compromise (inflammation, CD38 induction, Fe-S cluster damage).

For Driver 2 (mast cell) cases: mast cell stabilization (cromolyn, ketotifen, quercetin); H1 and H2 antihistamine combination where appropriate; low-histamine dietary trial (4-8 weeks with careful reintroduction); identify and address the Pattern A or Pattern B driver per the MCAS four-patterns framework.

For Driver 3 (small fiber neuropathy) cases: skin biopsy confirmation where accessible (consider Therapath Lab or comparable); alpha-lipoic acid (well-evidenced for small fiber neuropathy at 600-1200 mg daily); B12 methylcobalamin (5000 mcg daily for at least 3 months); B1 thiamine, particularly benfotiamine form; magnesium and the broader nerve cofactor stack; address metabolic factors including impaired glucose tolerance; consider IVIG referral in cases with documented autoimmune small fiber neuropathy.

For Driver 4 (gut-brain) cases: address SIBO if present per the recurrent SIBO framework; comprehensive stool panel and OAT testing; vagal tone restoration (slow-paced breath work, cold exposure within tolerance); address barrier failure through the broader Host Capacity Model gut approach; eliminate driving foods identified by clinical pattern (gluten, dairy, FODMAPs, histamine-rich foods as appropriate).

The full sequence operates on the timescale of six to twelve months for substantial improvement. Some patients experience earlier symptomatic improvement (particularly with mitochondrial cofactor support and mast cell stabilization, which can show effects within weeks). Full restoration of the bioenergetic state and resolution of the central sensitization takes longer.

This is the approach a Biomelogic consultation works through

The deliverable is a written mechanistic analysis that places the fibromyalgia case in HCM terms, identifies the dominant driver in the specific patient, names the contributing drivers, and recommends sequencing for the patient's existing clinical team to implement alongside the conventional rheumatology or pain management care. Biomelogic does not prescribe and does not replace the clinicians managing the case.

Frequently asked questions about fibromyalgia

Is fibromyalgia a real disease or "all in my head"?

Fibromyalgia is a real, organic, mechanistically definable condition. The "all in your head" framing reflects the historical limitations of the diagnostic workup that fibromyalgia patients are given. When the workup looks only for the diseases the workup was designed to detect, and does not find them, the alternative explanation that the symptoms have a different mechanistic basis was historically dismissed. The research literature has moved past this framing. Mitochondrial dysfunction, mast cell activation, small fiber neuropathy, and gut-brain axis dysfunction are all objectively documented in fibromyalgia populations. The disease has a substrate. The substrate is in a layer the standard workup does not measure.

Why don't Lyrica and Cymbalta work for me?

The most common reason is that the dominant driver in your case is producing peripheral input into central sensitization that the medications do not address. The medications reduce central amplification. They do not reduce the input. When the input continues, the response is partial. The framework above identifies four upstream drivers. Addressing the dominant driver in your specific case, alongside the central medications, typically produces meaningfully better response than the medications alone.

Can fibromyalgia be cured?

Cure is not the right framing. Substantial improvement is realistic for most cases with the right mechanistic stratification and the right sequenced interventions. Some patients achieve sustained remission. Others experience meaningful improvement in function and pain even when complete remission is not achieved. The trajectory depends on which drivers are dominant, how long the disease has been present, and how comprehensively the upstream work is addressed.

What about small fiber neuropathy?

Small fiber neuropathy is documented in approximately 30-50% of fibromyalgia patients on skin biopsy. The diagnosis matters because it shifts the treatment approach toward peripheral nerve support (alpha-lipoic acid, B12 methylcobalamin, addressing metabolic factors) alongside the central pain medications. If you have not been evaluated for small fiber neuropathy and you have features suggesting it (burning pain, temperature sensitivity, autonomic features), the evaluation is worth pursuing.

Why does my fibromyalgia get worse in perimenopause?

The hormonal modulation of inflammation and pain processing is substantial. Falling estrogen reduces some of the protective mechanisms that buffered the underlying drivers. Mast cell stability falls. Mitochondrial function is more sensitive to perturbation. The drivers that were operating sub-clinically often become clinical during perimenopause.

What about hEDS, POTS, and MCAS together with fibromyalgia?

The constellation of fibromyalgia, hEDS-spectrum hypermobility, POTS-spectrum autonomic dysfunction, MCAS, and IBS represents a recognized clinical pattern. The four conditions share substantial mechanistic overlap. Treatment that addresses the shared mechanisms produces benefit across all four. The four-pattern MCAS framework and the four-pathway POTS framework both apply.

Should I try alpha-lipoic acid for fibromyalgia?

The evidence for alpha-lipoic acid in fibromyalgia is reasonable, particularly in patients with documented or suspected small fiber neuropathy. The dose of 600-1200 mg daily is well-tolerated for most patients. The mechanism includes mitochondrial support, antioxidant effects, and peripheral nerve support. It is a reasonable addition to the supplement regimen in most fibromyalgia cases.

Is the Host Capacity Model recognized by rheumatology?

Not in this specific form. The individual mechanisms (mitochondrial dysfunction in fibromyalgia, mast cell involvement, small fiber neuropathy, gut-brain axis contributions) are increasingly recognized in the research literature. The integration into a clinical framework operating alongside conventional fibromyalgia care is novel work being developed through case experience.

Is Mohammed Attallah a doctor?

No. Mohammed Attallah is an independent systems-biology researcher and developer of the Host Capacity Model. He is not a licensed clinician. Biomelogic provides educational systems-biology analysis that operates alongside the client's existing licensed medical team, particularly the rheumatologist, pain specialist, or integrative practitioner managing the fibromyalgia. Fibromyalgia requires ongoing clinical care and the framework does not replace that care.

Working with Biomelogic on fibromyalgia

If the patterns described above resonate with the fibromyalgia case you have been navigating, a Biomelogic consultation may be useful. The work is appropriate for patients with an established clinical team, who are interested in understanding the mechanistic layer that conventional fibromyalgia care does not address, and who are willing to do the slow upstream work alongside the medical management.

The lowest-friction starting point is the free 15-minute discovery call. The call is not medical advice and not a sales pitch. It exists to determine whether the framework is appropriate for the case.

Related articles

Selected primary research

  • Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain. 2013;154(11):2310-2316.
  • Cordero MD, Alcocer-Gómez E, de Miguel M, et al. Coenzyme Q10: a novel therapeutic approach for fibromyalgia? Case series with 5 patients. Mitochondrion. 2011;11(4):623-625.
  • Cordero MD, De Miguel M, Carmona-López I, et al. Oxidative stress and mitochondrial dysfunction in fibromyalgia. Neuro Endocrinol Lett. 2010;31(2):169-173.
  • Sánchez-Domínguez B, Bullón P, Román-Malo L, et al. Oxidative stress, mitochondrial dysfunction and inflammation common events in skin of patients with Fibromyalgia. Mitochondrion. 2015;21:69-75.
  • Theoharides TC, Tsilioni I, Bawazeer M. Mast cells, neuroinflammation and pain in fibromyalgia syndrome. Front Cell Neurosci. 2019;13:353.
  • Marum AP, Moreira C, Saraiva F, et al. A low fermentable oligo-di-mono-saccharides and polyols (FODMAP) diet reduced pain and improved daily life in fibromyalgia patients. Scand J Pain. 2017;17:166-170.
  • Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63(4):450-452.
  • Doppler K, Rittner HL, Deckart M, Sommer C. Reduced dermal nerve fiber diameter in skin biopsies of patients with fibromyalgia. Pain. 2015;156(11):2319-2325.